Search | Clinical Trials Finder

Conditions: Non-Small Cell Lung Cancer
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more

Conditions: Bariatric Surgery Candidate, Bone Loss
Interventions: Denosumab, Placebo, Zoledronic Acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Zoledronic acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 92
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Springdale, Arkansas + 81 more

Conditions: Paget's Disease of Bone
Interventions: Zoledronic Acid, Risedronate, Placebo to Risedronate, Placebo to Zoledronic Acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 12
States / cities: Santa Monica, California • Lakewood, Colorado • Boca Raton, Florida + 9 more

Conditions: Breast Neoplasms, Osteoporosis
Interventions: Zoledronic Acid, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 43
States / cities: Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more

Conditions: Multiple Myeloma Bone Disease
Interventions: BHQ880, Zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Boston, Massachusetts + 2 more

Conditions: Bone Loss, Prostate Cancer
Interventions: Zoledronic acid, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Zoledronic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D; Drug · Other · Dietary Supplement
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 238
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more

Conditions: Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Osteopenia, Osteoporosis
Interventions: Zoledronate, Zoledronate placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Interventions: AXS-02 (oral zoledronate), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 29
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more

Conditions: Pain, Bone Neoplasm, Neoplasm Metastasis
Interventions: ibandronate [Bondronat], zoledronic acid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 26
States / cities: Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more

Conditions: Osteoporosis
Interventions: Placebo, Acetaminophen, Fluvastatin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 79 Years · Female only
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Http://www.osteoporosisclinicalresearch.com, New Jersey

Conditions: Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions: Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 68 Years to 90 Years · Female only
Enrollment: 2,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 30
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more

Conditions: Post-menopausal Osteoporosis
Interventions: Placebo, Zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 10
States / cities: San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: Osteoporosis
Interventions: Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion; Drug
Lead sponsor: Chrissy Kistler; Other
Eligibility: 65 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: FHA (Functional Hypothalamic Amenorrhea)
Interventions: Romosozumab, Placebo, Zoledronic acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 30 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Osteopenia
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Zoledronate, Placebo (Saline); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post Menopausal Osteoporosis
Interventions: Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more

Conditions: Osteoporosis, Post-menopausal
Interventions: Teriparatide, Zoledronic Acid; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 89 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more

Search by objective public record fields.

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

Romosozumab Use to Build Skeletal Integrity

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Preserving Geriatric Muscle With an Osteoporosis Medication

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women